Peer-reviewed veterinary case report
Safety of giving dexrazoxane with doxorubicin in dogs with cancer
By FitzPatrick, W M et al.·Published in Veterinary and comparative oncology·2010·Department of Small Animal Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Safety of concurrent administration of dexrazoxane and doxorubicin in the canine cancer patient.
- Species:
- dog
Plain-English summary
A group of 25 dogs with cancer were treated with a combination of doxorubicin, a common chemotherapy drug, and dexrazoxane, which helps protect the heart from potential damage caused by doxorubicin. The dogs received an average of two doses of dexrazoxane, and the treatment was generally well tolerated with few side effects. While some dogs had received a higher cumulative dose of doxorubicin before starting dexrazoxane, they still managed to handle the treatment without serious issues. More research is needed to fully understand how dexrazoxane can protect the heart during cancer treatment.
People also search for: dog cancer treatment doxorubicin dexrazoxane · side effects of doxorubicin in dogs · heart protection during dog chemotherapy
Abstract
Doxorubicin may cause a rare but serious cardiotoxicity. Dexrazoxane is a cardioprotectant drug used to reduce the risk of cardiotoxicity in human patients. In this study, 25 tumour-bearing dogs were treated with concurrent doxorubicin and dexrazoxane. The total number of doses of dexrazoxane given was 54 (range 1-5 doses per dog, median 2 doses). Five dogs received more than 165 mg m(2) cumulative doxorubicin dose before starting dexrazoxane. Haematologic, gastrointestinal and cardiovascular toxicities were considered tolerable. The combination of doxorubicin with dexrazoxane was well tolerated with minimal side-effects in this patient cohort. Future studies are required to evaluate potential cardioprotective effects of dexrazoxane given concurrently with doxorubicin.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/21062409/